Your request to link to rcsb for Dihydrofolate reductase

---

• 1DHF: crystal structures of recombinant human dihydrofolate reductase complexed with folate and 5-deazofolate (10.1021/BI00492A021 )
• 1DLR: methotrexate-resistant variants of human dihydrofolate reductase with substitution of leucine 22: kinetics, crystallography and potential as selectable markers (10.1074/JBC.270.10.5057 )
• 1DLS: methotrexate-resistant variants of human dihydrofolate reductase with substitution of leucine 22: kinetics, crystallography and potential as selectable markers (10.1074/JBC.270.10.5057 )
• 1DRF: crystal structure of human dihydrofolate reductase complexed with folate (10.1111/J.1432-1033.1988.TB14108.X )
• 1HFP: comparison of ternary crystal complexes of human dihydrofolate reductase with nadph and a classical antitumor furopyrimdine
• 1HFQ: comparison of ternary crystal complexes of human dihydrofolate reductase with nadph and a classical antitumor furopyrimdine
• 1HFR: comparison of ternary crystal complexes of human dihydrofolate reductase with nadph and a classical antitumor furopyrimdine
• 1KMS: human dihydrofolate reductase complexed with nadph and 6- ([5-quinolylamino]methyl)-2,4-diamino-5-methylpyrido[2,3- d]pyrimidine (sri-9439), a lipophilic antifolate (10.1016/S0022-2836(02)00469-2 )
• 1KMV: human dihydrofolate reductase complexed with nadph and (z)- 6-(2-[2,5-dimethoxyphenyl]ethen-1-yl)-2,4-diamino-5- methylpyrido[2,3-d]pyrimidine (sri-9662), a lipophilic antifolate (10.1016/S0022-2836(02)00469-2 )
• 1MVS: analysis of two polymorphic forms of a pyrido[2,3-d]pyrimidine n9-c10 reverse-bridge antifolate binary complex with human dihydrofolate reductase (10.1107/S0907444903001951 )
• 1MVT: analysis of two polymorphic forms of a pyrido[2,3-d]pyrimidine n9-c10 reverse-bridge antifolate binary complex with human dihydrofolate reductase (10.1107/S0907444903001951 )
• 1OHJ: human dihydrofolate reductase, monoclinic (p21) crystal form (10.1021/BI971711L )
• 1OHK: human dihydrofolate reductase, orthorhombic (p21 21 21) crystal form (10.1021/BI971711L )
• 1PD8: analysis of three crystal structure determinations of a 5- methyl-6-n-methylanilino pyridopyrimidine antifolate complex with human dihydrofolate reductase (10.1107/S0907444903014963 )
• 1PD9: analysis of three crystal structure determinations of a 5- methyl-6-n-methylanilino pyridopyrimidine antifolate complex with human dihydrofolate reductase (10.1107/S0907444903014963 )
• 1PDB: analysis of three crystal structure determinations of a 5- methyl-6-n-methylanilino pyridopyrimidine antifolate complex with human dihydrofolate reductase (10.1107/S0907444903014963 )
• 1S3U: structure determination of tetrahydroquinazoline antifolates in complex with human and pneumocystis carinii dihydrofolate reductase: correlations of enzyme selectivity and stereochemistry (10.1107/S0907444904002094 )
• 1S3V: structure determination of tetrahydroquinazoline antifolates in complex with human and pneumocystis carinii dihydrofolate reductase: correlations of enzyme selectivity and stereochemistry (10.1107/S0907444904002094 )
• 1S3W: structure determination of tetrahydroquinazoline antifoaltes in complex with human and pneumocystis carinii dihydrofolate reductase: correlations of enzyme selectivity and stereochemistry (10.1107/S0907444904002094 )
• 1U70: understanding the role of leu22 variants in methotrexate resistance: comparison of wild-type and leu22arg variant mouse and human dihydrofolate reductase (10.1107/S0907444904030422 )
• 1U71: understanding the role of leu22 variants in methotrexate resistance: comparison of wild-type and leu22arg variant mouse and human dihydrofolate reductase ternary crystal complexes with methotrexate and nadph (10.1107/S0907444904030422 )
• 1U72: understanding the role of leu22 variants in methotrexate resistance: comparison of wild-type and leu22arg variant mouse and human dihydrfolate reductase ternary crystal complexes with methotrexate and nadph (10.1107/S0907444904030422 )
• 1YHO: solution structure of human dihydrofolate reductase complexed with trimethoprim and nadph, 25 structures (10.1007/S10858-005-1475-Z )
• 2C2S: human dihydrofolate reductase complexed with nadph and 2,4-diamino-5- (1-o-carboranylmethyl)-6-methylpyrimidine, a novel boron containing, nonclassical antifolate (10.1021/JM0701977 )
• 2C2T: human dihydrofolate reductase complexed with nadph and 2,4-diamino-5- ((7,8-dicarbaundecaboran-7-yl)methyl)-6-methylpyrimidine, a novel boron containing, nonclassical antifolate (10.1021/JM0701977 )
• 2DHF: crystal structures of recombinant human dihydrofolate reductase complexed with folate and 5-deazofolate (10.1021/BI00492A021 )
• 2FZJ: new insights into dhfr interactions: analysis of pneumocystis carinii and mouse dhfr complexes with nadph and two highly potent trimethoprim derivatives (10.1002/PROT.21131 )
• 2W3A: human dihydrofolate reductase complexed with nadph and trimethoprim
• 2W3B: human dihydrofolate reductase complexed with nadph and a lipophilic antifolate selective for mycobacterium avium dhfr, 6-((2,5- diethoxyphenyl)aminomethyl)-2,4-diamino-5-methylpyrido(2,3-d) pyrimidine (sri-8686)
• 2W3M: human dihydrofolate reductase complexed with nadph and folate
• 3D80: structural analysis of a holo enzyme complex of mouse dihydrofolate reductase with nadph and a ternary complex wtih the potent and selective inhibitor 2,4-diamino-6-(2'-hydroxydibenz[b,f]azepin-5-yl) methylpteridine (10.1107/S0907444908022348 )
• 3D84: structural analysis of a holo enzyme complex of mouse dihydrofolate reductase with nadph and a ternary complex with the potent and selective inhibitor 2.4-diamino-6-(-2'-hydroxydibenz[b,f]azepin-5- yl)methylpteridine (10.1107/S0907444908022348 )
• 3EIG: crystal structure of a methotrexate-resistant mutant of human dihydrofolate reductase (10.1074/JBC.M109.018010 )
• 3F8Y: correlations of human dihydrofolate reductase with structural data for human active site mutant enzyme complexes (10.1021/BI801960H )
• 3F8Z: human dihydrofolate reductase structural data with active site mutant enzyme complexes (10.1021/BI801960H )
• 3F91: structural data for human active site mutant enzyme complexes (10.1021/BI801960H )
• 3FS6: correlations of inhibitor kinetics for pneumocystis jirovecii and human dihydrofolate reductase with structural data for human active site mutant enzyme complexes (10.1021/BI801960H )
• 3GHC: design, synthesis, and x-ray crystal structure of classical and nonclassical 2-amino-4-oxo-5-substituted-6-thieno[2,3- d]pyrimidines as dual thymidylate synthase and dihydrofolate reductase inhibitors and as potential antitumor agenst (10.1021/JM900490A )
• 3GHV: human dihydrofolate reductase q35k/n64f double mutant inhibitor complex (10.1021/JM900490A )
• 3GHW: human dihydrofolate reductase inhibitor complex (10.1021/JM900490A )
• 3GI2: human dihydrofolate reductase q35k mutant inhibitor complex (10.1021/JM900490A )
• 3GYF: human dhfr with z-isomer in orthorhombic lattice (10.1107/S1744309109025548 )
• 3K45: alternate binding modes observed for the e- and z-isomers of 2,4- diaminofuro[2,3d]pyrimidines as ternary complexes with nadph and mouse dihydrofolate reductase (10.1016/J.BMC.2009.08.044 )
• 3K47: alternate binding modes observed for the e- and z-isomers of 2,4- diaminofuro[2,3-d]pyrimidines as ternary complexes with nadph and mouse dihydrofolate reductase (10.1016/J.BMC.2009.08.044 )
• 3L3R: structural, computational and kinetic data for antifolate interactions against pneumocystis jirovecii, pneumocystis carinii and human dihydrofolate reductase and their active site mutants (10.1128/AAC.00172-13 )
• 3N0H: hdhfr double mutant q35s/n64f trimethoprim binary complex (10.1016/J.JSB.2011.06.001 )
• 3NTZ: design, synthesis, biological evaluation and x-ray crystal structures of novel classical 6,5,6-tricyclicbenzo[4,5]thieno[2,3-d]pyrimidines as dual thymidylate synthase and dihydrofolate reductase inhibitors (10.1016/J.BMC.2011.03.067 )
• 3NU0: design, synthesis, biological evaluation and x-ray crystal structure of novel classical 6,5,6-tricyclicbenzo[4,5]thieno[2,3-d]pyrimidines as dual thymidylate synthase and dihydrofolate reductase inhibitors (10.1016/J.BMC.2011.03.067 )
• 3NXO: perferential selection of isomer binding from chiral mixtures: alternate binding modes observed for the e- and z-isomers of a series of 5-substituted 2,4-diaminofuro[2,3-d]pyrimidines as ternary complexes with nadph and human dihydrofolate reductase (10.1107/S0907444910035808 )
• 3NXR: perferential selection of isomer binding from chiral mixtures: alternate binding modes observed for the e- and z-isomers of a series of 5-substituted 2,4-diaminofuro[2,3-d]pyrimidines as ternary complexes with nadph and human dihydrofolate reductase (10.1107/S0907444910035808 )
• 3NXT: preferential selection of isomer binding from chiral mixtures: alternate binding modes observed for the e-and z-isomers of a series of 5-substituted 2,4-diaminofuro[2m,3-d]pyrimidines as ternary complexes with nadph and human dihydrofolate reductase (10.1107/S0907444910035808 )
• 3NXV: preferential selection of isomer binding from chiral mixtures: alternate binding modes observed for the e- and z-isomers of a series of 5-substituted 2,4-diaminofuro[2,3-d]pyrimidines as ternary complexes with nadph and human dihydrofolate reductase (10.1107/S0907444910035808 )
• 3NXX: preferential selection of isomer binding from chiral mixtures: alternate binding modes observed for the e- and z-isomers of a series of 5-substituted 2,4-diaminofuro-2,3-d]pyrimidines as ternary complexes with nadph and human dihydrofolate reductase (10.1107/S0907444910035808 )
• 3NXY: preferential selection of isomer binding from chiral mixtures: alernate binding modes observed fro the e- and z-isomers of a series of 5-substituted 2,4-diaminofuro[2,3-d]pyrimidines as ternary complexes with nadph and human dihydrofolate reductase (10.1107/S0907444910035808 )
• 3NZD: structural analysis of pneumocystis carinii and human dhfr complexes with nadph and a series of five 5-(omega-carboxy(alkyloxy(pyrido[2,3- d]pyrimidine derivatives (10.1107/S0907444910041004 )
• 3OAF: structural and kinetic data for antifolate interactions against pneumocystis jirovecii, pneumocystis carinii and human dihydrofolate reductase and thier active site mutants (10.1128/AAC.00172-13 )
• 3S3V: human dihydrofolate reductase q35k/n64f double mutant binary complex with trimethoprim (10.1016/J.JSB.2011.06.001 )
• 3S7A: human dihydrofolate reductase binary complex with pt684 (10.1107/S0907444911030071 )
• 4DDR: human dihydrofolate reductase complexed with nadph and p218 (10.1073/PNAS.1204556109 )
• 4G95: hdhfr-oag binary complex (10.1128/AAC.00172-13 )
• 4KAK: crystal structure of human dihydrofolate reductase complexed with nadph and 6-ethyl-5-[(3s)-3-[3-methoxy-5-(pyridine-4-yl)phenyl]but-1- yn-1-yl]pyrimidine-2,4-diamine (ucp1006) (10.1021/BI400852H )
• 4KBN: human dihydrofolate reductase complexed with nadph and 5-{3-[3-(3,5- pyrimidine)]-phenyl-prop-1-yn-1-yl}-6-ethyl-pyrimidine-2,4diamine (10.1021/BI400852H )
• 4KD7: human dihydrofolate reductase complexed with nadph and 5-{3-[3- methoxy-5(pyridine-4-yl)phenyl]prop-1-yn-1-yl}-6-ethyl-pyrimidine-2, 4-diamine (10.1021/BI400852H )
• 4KEB: human dihydrofolate reductase complexed with nadph and 5-{3-[3- methoxy-5-(isoquin-5-yl)phenyl]but-1-yn-1-yl}6-ethylpyrimidine-2,4- diamine (10.1021/BI400852H )
• 4KFJ: human dihydrofolate reductase complexed with nadph and 5-{3-[3- methoxy-5-(isoquin-5-yl)phenyl]prop-1-yn-1-yl}6-ethylprimidine-2,4- diamine (10.1021/BI400852H )
• 4M6J: crystal structure of human dihydrofolate reductase (dhfr) bound to nadph (10.1038/NSMB.2676 )
• 4M6K: crystal structure of human dihydrofolate reductase (dhfr) bound to nadp+ and folate (10.1038/NSMB.2676 )
• 4M6L: crystal structure of human dihydrofolate reductase (dhfr) bound to nadp+ and 5,10-dideazatetrahydrofolic acid (10.1038/NSMB.2676 )
• 4QHV: crystal structure of human dihydrofolate reductase as complex with pyridopyrimidine 22 (n~6~-methyl-n~6~-[4-(propan-2-yl) phenyl]pyrido[2,3-d]pyrimidine-2,4,6-triamine) (10.1107/S2053230X15008468 )
• 4QJC: human dihydrofolate reductase ternary complex with nadph and inhibitor 26 (n~6~-methyl-n~6~-(3,4,5-trifluorophenyl)pyrido[2,3-d]pyrimidine- 2,4,6-triamine) (10.1107/S2053230X15008468 )
• 5HPB: human dihydrofolate reductase complex with nadph and 5-methyl-6- (phenylthio-4'trifluoromethyl)thieno[2,3-d]pyrimidine-2,4-diamine
• 5HQY: human dihydrofolate reductase complex with nadph and 5-methyl-6-(2', 3',4'-trifluorophenylthio)thieno[2,3-d]pyrimidine-2,4-diamine
• 5HQZ: fluorine substituted 5-methyl-6-(4'-trifluoromethoxyphenythio) thieno[2,3-d]pyrimidine-2,4-diamine
• 5HSR: fluorine substituted 5-methyl-6-(3',4'-difluoromethoxyphenythio) thieno[2,3-d]pyrimidine-2,4-diamine
• 5HSU: fluorine substituted 5-methyl-6-(2',4'-difluoromethoxyphenythio) thieno[2,3-d]pyrimidine-2,4-diamine
• 5HT4: 6-substituted pyrrolo[2,3-d]pyrimidine 6-thieno-(4-methoxyphenyl)
• 5HT5: 6-substituted pyrrolo[2,3-d]pyrimidine 6-thieno-(4-methoxyphenyl)
• 5HUI: 6-substituted pyrido[3,2-d]pyrimidine--6-4'-trifluoromethoxyphenyl)
• 5HVB: 5-methyl-6-(1-naphthylthio)thieno[2,3-d]pyrimidine 2,4-diamine
• 5HVE: 5-methyl-6-(3'-trifluromethoxyphenylthio)[2,3-d]pyrimidine 2,4-diamine
• 6A7C: human dihydrofolate reductase complexed with nadph and bt1 (10.1021/ACSMEDCHEMLETT.8B00389 )
• 6A7E: human dihydrofolate reductase complexed with nadph and bt2 (10.1021/ACSMEDCHEMLETT.8B00389 )
• 6DAV: crystal structure of human dhfr complexed with nadp and n10formyltetrahydrofolate
• 6DE4: homo sapiens dihydrofolate reductase complexed with beta-nadph and 3'- [(2r)-4-(2,4-diamino-6-ethylphenyl)but-3-yn-2-yl]-5'-methoxy-[1,1'- biphenyl]-4-carboxylic acid (10.1016/J.CHEMBIOL.2019.02.013 )
• 6VCJ: crystal structure of hsdhfr in complex with nadp+, dap, and r-naproxen (10.1021/ACS.JMEDCHEM.0C00546 )
• 7ESE: the crystal structure of human dhfr from biortus